- Home
- SSTK vs GERN Comparison
SSTK vs GERN Comparison
Compare SSTK & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSTK
- GERN
- Stock Information
- Founded
- SSTK 2003
- GERN 1990
- Country
- SSTK United States
- GERN United States
- Employees
- SSTK N/A
- GERN N/A
- Industry
- SSTK EDP Services
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- SSTK Technology
- GERN Health Care
- Exchange
- SSTK Nasdaq
- GERN Nasdaq
- Market Cap
- SSTK 668.4M
- GERN 700.6M
- IPO Year
- SSTK 2012
- GERN 1996
- Fundamental
- Price
- SSTK $21.91
- GERN $1.46
- Analyst Decision
- SSTK Buy
- GERN Buy
- Analyst Count
- SSTK 4
- GERN 8
- Target Price
- SSTK $43.67
- GERN $3.71
- AVG Volume (30 Days)
- SSTK 271.5K
- GERN 12.0M
- Earning Date
- SSTK 07-29-2025
- GERN 08-06-2025
- Dividend Yield
- SSTK 6.00%
- GERN N/A
- EPS Growth
- SSTK 38.48
- GERN N/A
- EPS
- SSTK 1.81
- GERN N/A
- Revenue
- SSTK $1,010,504,000.00
- GERN $164,447,000.00
- Revenue This Year
- SSTK $10.45
- GERN $159.14
- Revenue Next Year
- SSTK $3.19
- GERN $52.76
- P/E Ratio
- SSTK $12.13
- GERN N/A
- Revenue Growth
- SSTK 14.20
- GERN 11877.20
- 52 Week Low
- SSTK $14.35
- GERN $1.09
- 52 Week High
- SSTK $38.80
- GERN $4.83
- Technical
- Relative Strength Index (RSI)
- SSTK 60.81
- GERN 59.63
- Support Level
- SSTK $20.92
- GERN $1.26
- Resistance Level
- SSTK $22.45
- GERN $1.55
- Average True Range (ATR)
- SSTK 0.96
- GERN 0.09
- MACD
- SSTK 0.08
- GERN 0.02
- Stochastic Oscillator
- SSTK 82.12
- GERN 75.00
About SSTK Shutterstock Inc.
Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market, but also has its presence in Europe and Rest of the Countries.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.